Appendix Cancer Treatment

Appendiceal cancer is a rare malignancy that begins in the appendix, a small, narrow pouch connected to the beginning of the large intestine. The appendix contains immune tissue and may help support beneficial bacteria in the digestive tract, although it is not essential for normal digestion. 

Treatment for appendiceal cancer can vary considerably depending on the specific type and grade of the tumor, whether it is confined to the appendix or has spread and other individual factors. Depending on these findings, treatment may be intended to eliminate the cancer, achieve long-term disease control or reduce symptoms caused by an advanced tumor.

At Moffitt Cancer Center, patients with appendiceal cancer receive specialized care through our comprehensive Gastrointestinal Oncology Program. Surgeons, medical oncologists, radiation oncologists, pathologists, radiologists and other specialists work together to develop an individualized treatment plan for each patient based on the tumor’s pathology, stage, molecular characteristics and pattern of spread.

Surgery for appendix cancer

Surgery plays a central role in treating many appendiceal cancers. The surgical oncologist works with other members of a multispecialty team to determine how much tissue must be removed based on the tumor’s histologic type, grade, size, location and extent of spread. Some procedures, including certain appendectomies, can be performed using minimally invasive laparoscopic techniques, while more extensive disease may require complex open abdominal surgery.

For selected patients whose appendix cancer has spread within the peritoneal cavity, Moffitt also offers cytoreductive surgery combined with HIPEC. This specialized approach is particularly important in the treatment of certain appendiceal cancers associated with peritoneal spread, including pseudomyxoma peritonei, but it is not appropriate for every patient. 

When is surgery a treatment option for appendix cancer?

Surgery may be recommended for localized appendiceal cancer as well as certain cancers that have spread within the abdomen. For a small tumor confined to the appendix, surgery may remove all of the cancer and provide the only treatment needed. More extensive surgery may be appropriate when the tumor involves nearby structures, lymph nodes or the peritoneum, the membrane that lines the abdominal cavity.

When cancer has spread throughout the peritoneum, surgeons evaluate factors such as the amount and location of disease, tumor grade, whether the visible cancer can be completely or nearly completely removed and the patient’s overall health. CRS/HIPEC is a major operation and is generally considered when the expected benefits justify the demands and risks of treatment. If the cancer cannot be safely removed, systemic therapy may become the primary treatment.

What are the different types of appendix cancer surgery?

Appendiceal cancer encompasses several distinct diseases, so there is no single operation that is appropriate for every patient. Surgical options may include:

Appendectomy

An appendectomy removes the appendix. It may be sufficient for certain early tumors that are confined to the appendix and have favorable pathological features. Many appendiceal neuroendocrine tumors smaller than 1 centimeter, for example, can be cured with appendectomy alone.

Right hemicolectomy

A right hemicolectomy removes the right portion of the colon along with associated lymph nodes and blood vessels. It may be considered for certain appendiceal adenocarcinomas and neuroendocrine tumors when pathological findings indicate a greater risk of lymph node involvement. For appendiceal neuroendocrine tumors, factors such as tumor size, location and pathological risk features help determine whether additional surgery is appropriate after an appendectomy.

Cytoreductive surgery and HIPEC

CRS is an extensive procedure used for selected appendix cancers that have spread along the peritoneal surfaces. The surgeon removes as much visible tumor as possible, which can require removing involved portions of the peritoneum and, in some cases, affected abdominal organs or tissues.

After the visible cancer is removed, HIPEC may be performed during the same operation. Heated chemotherapy is circulated directly throughout the abdominal cavity to expose microscopic cancer cells that may remain after surgery to a concentrated dose of chemotherapy. Because HIPEC is delivered within the abdomen rather than through the bloodstream, it differs from systemic chemotherapy, allowing a high concentration of medication to come into direct contact with the abdominal surfaces while limiting exposure throughout the rest of the body.

For some patients, especially those who have an aggressive or difficult-to-treat type of cancer, CRS/HIPEC may lead to a better outcome and enhanced quality of life.

Sean Dineen, MD

What are the risks and possible side effects of surgery for appendix cancer?

The possible side effects of surgery depend heavily on the extent of the procedure. An appendectomy generally requires a much shorter recovery than CRS/HIPEC. The surgical team explains the expected risks in advance and takes steps to prevent and manage complications, such as:

• Pain and limited mobility – Abdominal discomfort is expected after surgery, particularly after a large incision. Pain medication and progressively increasing physical activity can help the patient regain mobility while the incision heals.
• Temporary changes in bowel function – Abdominal and intestinal surgery can cause constipation, diarrhea, bloating or changes in bowel habits. The healthcare team may recommend temporary dietary modifications, medications and gradual reintroduction of foods as bowel function recovers.
• Nausea or reduced appetite – Surgery and HIPEC can temporarily make eating difficult. Antinausea medication and support from an oncology dietitian can help the patient maintain adequate nutrition and hydration.
• Infection or delayed wound healing – Any abdominal operation carries a risk of infection. The surgical team monitors the incision and other potential infection sites and provides treatment promptly if signs such as fever, redness or drainage develop.
• Bleeding or blood clots – Major abdominal surgery can increase these risks. Early walking, compression devices and medications when appropriate can help reduce the likelihood of blood clots.
• Fluid or kidney problems after HIPEC – Heated intraperitoneal chemotherapy can affect fluid balance and, depending on the medications used, kidney function. Careful monitoring of side effects, fluids, laboratory values and kidney function is incorporated into perioperative care.

What is the recovery process like after surgery for appendix cancer?

Recovery varies considerably according to the operation. A patient undergoing an uncomplicated minimally invasive appendectomy may leave the hospital relatively quickly and gradually resume normal activities over the following weeks. A patient undergoing CRS/HIPEC generally requires a hospital stay of several days or longer followed by a more gradual recovery at home. Full recovery from this complex procedure may take several weeks to months.

During recovery, the healthcare team monitors wound healing, bowel function, nutrition and physical activity. Dietary adjustments may be necessary while the digestive tract recovers, and patients are generally encouraged to increase walking and other activity gradually as their strength returns.

Systemic chemotherapy for appendix cancer

Systemic therapy refers to medications that enter the bloodstream and travel throughout the body to reach cancer cells in multiple locations. For appendix cancer, systemic chemotherapy is used primarily for certain epithelial cancers, including appendiceal adenocarcinoma. Treatment recommendations depend on tumor type and grade, previous treatment, extent of disease, molecular findings and the patient’s overall health.

Appendiceal neuroendocrine tumors have different biology and are managed differently from appendiceal adenocarcinomas, so colorectal-type chemotherapy regimens are not automatically appropriate for every appendix cancer.

When is chemotherapy used for appendix cancer?

Systemic chemotherapy may be incorporated at several points in treatment. It may be given before an operation in selected cases to treat disease that has spread and potentially improve the feasibility of surgery. It can also be recommended after surgery for certain higher-risk cancers to address microscopic cancer cells that may remain elsewhere in the body.

For appendiceal cancer that cannot be completely removed or has spread to distant organs, chemotherapy may serve as the main systemic treatment to control cancer growth. Because prospective studies specifically involving appendix cancer are limited, many systemic treatment strategies for appendiceal adenocarcinoma have historically been adapted from the treatment of colorectal cancer.

Which chemotherapy drugs are used for appendix cancer?

The optimal regimen depends on the tumor’s histology, grade and clinical circumstances. For appendiceal adenocarcinoma, commonly considered colorectal-type chemotherapy combinations include:

• FOLFOX – This regimen combines folinic acid, fluorouracil (5-FU) and oxaliplatin. The medications interfere with cancer cell growth through complementary mechanisms.
• CAPOX – This combination uses oral capecitabine, which is converted to 5-FU in the body, with intravenous oxaliplatin.
• FOLFIRI – This regimen combines folinic acid, 5-FU and irinotecan and may be considered in certain advanced-disease settings.
• FOLFOXIRI – This intensive combination of folinic acid, 5-FU, oxaliplatin and irinotecan may be considered in select circumstances based on treatment strategies used for colorectal cancer.

Depending on the tumor’s characteristics and treatment setting, chemotherapy may also be combined with a biological or targeted agent. Because appendiceal cancer is biologically distinct from colorectal cancer and appendix-specific clinical evidence remains limited, the medical oncology team determines whether such combinations are appropriate for an individual patient.

What are the risks and possible side effects of chemotherapy for appendix cancer?

Risks and side effects of chemotherapy depend on the medications and doses used, and many can be prevented or reduced with supportive care or treatment adjustments. Possible side effects of traditional chemotherapy include:

• Fatigue – Chemotherapy and temporary changes in blood counts can reduce energy. Planned rest, light physical activity when tolerated and evaluation for contributing factors such as anemia can help manage fatigue.
• Nausea, diarrhea or appetite changes – Fluoropyrimidines, irinotecan and other chemotherapy drugs can affect the digestive tract. Antinausea medications, antidiarrheal medications, adequate hydration and nutrition support can help control these symptoms.
• Cold sensitivity and peripheral neuropathy – Oxaliplatin can cause temporary sensitivity to cold and, with repeated treatment, numbness or tingling in the hands and feet. Avoiding cold exposure after an infusion and promptly reporting persistent symptoms can allow the treatment team to adjust therapy if necessary.
• Low blood cell counts – Chemotherapy can temporarily decrease white blood cells, red blood cells or platelets. Regular blood tests allow the healthcare team to identify significant changes and use treatment delays, dose adjustments or supportive medications when appropriate.
• Mouth sores – Fluoropyrimidines can irritate the lining of the mouth. Gentle oral hygiene and prescribed mouth rinses or other medications can help reduce discomfort and support healing.
• Hand-foot syndrome – Capecitabine can cause redness, tenderness or peeling of the palms and soles. Moisturizers, avoidance of excessive heat or friction and early communication with the treatment team can help prevent symptoms from becoming severe.

How does chemotherapy for appendix cancer affect daily life, and what is the recovery process like?

Traditional chemotherapy is generally given in cycles, with treatment periods followed by time for the body to recover. Intravenous medications may be delivered through a vein in the arm or through an implanted port, depending on the treatment regimen and how often therapy is needed. Some regimens include a portable infusion pump that delivers 5-FU continuously over approximately two days. Capecitabine is taken by mouth on a prescribed schedule.

Energy and other side effects may fluctuate during each cycle. Some patients feel relatively well between treatments, while others require more time to recover. Blood counts and other laboratory values are monitored throughout treatment, and doses or schedules can be modified when necessary.

Tampa's #1 Cancer Hospital

Ranked #1 Hospital for Cancer Care in U.S. News & World Report's list of America's Best Hospitals in Tampa and ranked #26 in the nation.

Schedule an Appointment

Radiation therapy for appendix cancer

Radiation therapy uses high-energy beams or particles to damage cancer cell DNA and prevent the cells from continuing to grow. Unlike systemic chemotherapy, radiation therapy is a localized treatment directed at a specific part of the body.

Radiation therapy is rarely a primary treatment for appendiceal cancer. When it is appropriate, radiation oncologists work with medical physicists and other specialists to carefully plan treatment and limit radiation exposure to surrounding healthy organs and tissues.

How does radiation therapy treat appendix cancer?

Radiation therapy may be considered in select circumstances, such as when appendiceal cancer has spread to a specific location and local treatment could help control the disease or reduce symptoms. Its role depends on the tumor type, location and treatments the patient has already received.

Because radiation therapy is not routinely used for most appendix cancers, there is no single standard radiation technique or schedule that applies to all patients. When radiation therapy is recommended, the radiation oncology team selects the delivery method, dose and number of treatments based on the specific site being treated.

What are the possible side effects of radiation therapy for appendix cancer?

Side effects of radiation therapy are largely determined by the area of the body exposed and the dose delivered. Some patients may experience:

• Fatigue – Energy levels may gradually decline during a course of radiation therapy. Balancing rest with light activity and maintaining adequate nutrition can help the patient manage fatigue.
• Skin changes – Skin within the treatment field can become dry, sensitive or irritated. The radiation oncology team can recommend appropriate skin care and topical products.
• Digestive symptoms – Radiation therapy involving the abdomen or pelvis may cause nausea, diarrhea, cramping or changes in bowel habits. Dietary adjustments and medications can often help control these effects.
• Long-term tissue changes – Depending on the treatment location and dose, radiation can occasionally cause lasting changes in nearby tissues or organs. Precise treatment planning is used to reduce unnecessary exposure whenever possible.

Immunotherapy and targeted therapy for appendix cancer

Molecular testing can provide additional information about an appendix tumor and, in selected cases, identify a treatment opportunity. This is particularly relevant for advanced disease when standard surgery or chemotherapy alone may not provide adequate cancer control.

Appendiceal cancers have molecular profiles that differ according to histologic subtype and also differ from conventional colorectal cancer. Common alterations can include changes involving KRAS, GNAS, TP53, SMAD4 and BRAF, although finding a mutation does not necessarily mean that an approved targeted treatment is available or appropriate.

How does immunotherapy work for appendix cancer?

Immune checkpoint inhibitors block signals that cancer cells can use to suppress an immune response, allowing immune cells to better recognize and attack the cancer. These medications are not routinely effective against all appendiceal cancers.

Immunotherapy may be considered when testing identifies a biomarker associated with response, particularly microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR). These findings appear to be uncommon in many appendix cancer subtypes.

Which biomarkers can help guide immunotherapy and targeted therapy for appendix cancer?

The exact molecular testing panel depends on the tumor type and clinical setting. For advanced appendiceal adenocarcinoma, testing may assess biomarkers that could influence treatment selection or clinical trial eligibility, including:

• Mismatch repair and microsatellite instability – dMMR or MSI-H tumors may be susceptible to immune checkpoint inhibitors.
• KRAS and NRAS – Alterations in RAS genes can affect whether therapies directed at the EGFR signaling pathway are biologically appropriate.
• BRAF – Certain BRAF alterations can create a potential target for combinations of targeted medications.
• HER2, also known as ERBB2 – Amplification or overexpression may provide a treatment target in a small subset of tumors.
• NTRK gene fusions – Although rare, these alterations can make a tumor eligible for drugs specifically designed to inhibit TRK proteins.

Other alterations may be identified through comprehensive genomic profiling and can sometimes help the treatment team identify an appropriate clinical trial. Molecular testing does not replace tumor type, grade and stage in treatment planning, and not every detected alteration is actionable.

What are the possible side effects of immunotherapy for appendix cancer?

Checkpoint immunotherapy has a different side effect profile from conventional chemotherapy. Because these drugs increase immune activity, they can sometimes cause the immune system to inflame healthy organs and tissues. Symptoms may include:

• Skin inflammation – Rash and itching can develop and should be reported so topical treatments or other medications can be started when needed.
• Intestinal inflammation – Immune-related colitis can cause persistent diarrhea or abdominal pain. Prompt evaluation is important because treatment may require corticosteroids or other medications that suppress the immune response.
• Lung inflammation – Pneumonitis can cause a new cough or shortness of breath. These symptoms require timely evaluation and may require interruption of immunotherapy and treatment with corticosteroids.
• Liver inflammation – Hepatitis may initially cause no noticeable symptoms, which is why liver function is monitored with blood tests throughout treatment.
• Hormone gland inflammation – Immunotherapy can affect the thyroid, pituitary or adrenal glands. Blood testing can identify hormonal changes, and hormone replacement therapy may be used when necessary.

Early recognition is important because many immune-related side effects can be controlled more effectively when treatment begins promptly.

Appendix cancer clinical trials at Moffitt Cancer Center

Because appendiceal cancer is rare and includes several biologically distinct tumor types, clinical research is especially important for improving treatment. Moffitt is a National Cancer Institute (NCI)-designated Comprehensive Cancer Center with a robust clinical trials program investigating new approaches to gastrointestinal cancers, including appendix cancer.

Eligible patients may have opportunities to participate in studies evaluating new surgical strategies, systemic therapies, drug combinations or other treatment approaches for appendix cancer. A clinical trial may be considered at different points in the treatment process depending on the patient’s diagnosis, previous therapies and the requirements of the study.

Why should a patient consider a clinical trial for appendix cancer?

Clinical trials can allow a patient to access investigational treatments that are not yet widely available while contributing to research that may improve care for future patients. For a rare cancer such as appendiceal cancer, a trial can be particularly relevant when standard treatment options are limited or researchers are studying therapies designed for a specific molecular characteristic of the tumor.

Moffitt’s specialists can review available studies and determine whether a patient meets the eligibility criteria for a trial that is appropriate for the specific type and stage of appendix cancer.

Frequently asked questions (FAQs) about appendix cancer treatment

Treatment decisions can differ significantly from one patient to another because appendiceal cancer encompasses several tumor types. The following answers address several common questions about treatment.

Is surgery always required to treat appendix cancer?

No. Although surgery is the primary treatment for many localized appendiceal cancers and selected cancers that have spread within the abdomen, it is not appropriate for every patient. If the cancer cannot be safely or completely removed, systemic therapy or another treatment approach may be recommended.

What is HIPEC, and how is it used for appendix cancer?

HIPEC stands for hyperthermic intraperitoneal chemotherapy. After cytoreductive surgery removes visible tumors from the abdominal cavity, heated chemotherapy is circulated throughout the abdomen to treat microscopic cancer cells that may remain. CRS/HIPEC is used for selected appendiceal cancers that have spread to the peritoneum.

Can appendix cancer be cured if it spreads to the peritoneum?

Peritoneal spread does not automatically rule out an aggressive treatment approach. Selected patients whose cancer is confined predominantly to the abdominal cavity and can be completely or nearly completely removed may be candidates for CRS/HIPEC. Whether this approach offers the possibility of long-term disease control depends on factors such as tumor type and grade, the extent of peritoneal disease and the completeness of surgical removal.

Does every patient with appendix cancer need chemotherapy?

No. Some localized tumors can be adequately treated with surgery alone, while chemotherapy is more likely to be considered for certain higher-risk, advanced or unresectable appendiceal cancers. The tumor’s histology and grade are particularly important when determining whether systemic chemotherapy is likely to provide a benefit.

Is appendix cancer treated the same way as colon cancer?

Not necessarily. Some chemotherapy strategies used for appendiceal adenocarcinoma have been adapted from colorectal cancer treatment because appendix-specific clinical trials are limited. However, appendiceal cancers have distinct pathological and molecular characteristics, and treatment should be individualized rather than assuming that an appendix tumor will behave like colon cancer.

Appendix cancer can spread and behave differently from colon cancer, so treatment should be based on the specific tumor rather than a one-size-fits-all approach.

Michael Wach, MD

Why choose Moffitt Cancer Center for appendix cancer treatment

Because appendix cancer is uncommon and can vary substantially in its behavior, evaluation by a team of specialists who regularly treat gastrointestinal malignancies can be especially valuable. Moffitt’s Gastrointestinal Oncology Program brings together surgical oncologists, medical oncologists, radiation oncologists, pathologists, radiologists and other experts to evaluate the diagnosis and determine which treatments are appropriate for the individual patient. Moffitt is a high-volume cancer center and offers complex treatments for peritoneal surface malignancies, including CRS/HIPEC.

A patient who has already received an appendix cancer diagnosis elsewhere can also come to Moffitt for a second opinion. Our subspecialized pathologists can review tissue to confirm the precise tumor type and grade, while our radiologists and other specialists can assess the extent and pattern of disease. When appropriate, molecular testing can provide additional information that may influence systemic treatment or clinical trial options.

As an NCI-designated Comprehensive Cancer Center, Moffitt also conducts research aimed at advancing treatment for appendix cancer and other gastrointestinal malignancies. Eligible patients may have access to clinical trials evaluating new therapies and treatment strategies.

If you would like to learn more about appendix cancer treatment, you can request an appointment with a specialist in the Gastrointestinal Oncology Program at Moffitt by calling 1-888-663-3488 or submitting a new patient registration form online. We do not require referrals.